All News

The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.

Data for GC reduction and improved A4 levels were consistent across subgroups stratified by sex, race, age, BMI, and baseline A4 levels, according to Neurocrine Biosciences.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

The investigational mRNA-1083 vaccine induced superior immune responses against all 4 flu strains in adults aged 50-64 years and against 3 in adults 65 and older.

Your daily dose of the clinical news you may have missed.

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Your daily dose of the clinical news you may have missed.